PREMPHASE 14/14 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Premphase 14/14, and what generic alternatives are available?
Premphase 14/14 is a drug marketed by Wyeth Pharms and is included in one NDA.
The generic ingredient in PREMPHASE 14/14 is estrogens, conjugated; medroxyprogesterone acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated; medroxyprogesterone acetate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PREMPHASE 14/14?
- What are the global sales for PREMPHASE 14/14?
- What is Average Wholesale Price for PREMPHASE 14/14?
Summary for PREMPHASE 14/14
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 410 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PREMPHASE 14/14 |
| DailyMed Link: | PREMPHASE 14/14 at DailyMed |
Pharmacology for PREMPHASE 14/14
| Drug Class | Estrogen Progestin |
| Mechanism of Action | Estrogen Receptor Agonists |
US Patents and Regulatory Information for PREMPHASE 14/14
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PREMPHASE 14/14
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | 5,210,081 | ⤷ Start Trial |
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | RE36247 | ⤷ Start Trial |
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | 5,547,948 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PREMPHASE 14/14
See the table below for patents covering PREMPHASE 14/14 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 147987 | ⤷ Start Trial | |
| Australia | 3140584 | ⤷ Start Trial | |
| Australia | 582540 | ⤷ Start Trial | |
| Canada | 1240927 | METHODE DE TRAITEMENT DES TROUBLES DE LA PRE-MENOPAUSE, DE LA MENOPAUSE ET DE LA PORT-MENOPAUSE, COMPOSES ET CONDITIONNEMENT DES COMPOSES (METHOD OF TREATMENT OF PERIMENOPAUSAL, MENOPAUSAL AND POST-MENOPAUSAL DISORDER, COMPOSITIONS AND MULTI- PREPARATION PACK THEREFOR) | ⤷ Start Trial |
| Germany | 10075037 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PREMPHASE 14/14
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0136011 | C00136011/03 | Switzerland | ⤷ Start Trial | PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417 |
| 0136011 | SPC/GB00/025 | United Kingdom | ⤷ Start Trial | SPC/GB00/025: 20040802, EXPIRES: 20090801 |
| 0136011 | SPC/GB02/008 | United Kingdom | ⤷ Start Trial | SPC/GB02/008: 20040802, EXPIRES: 20090801 |
| 0136011 | SPC/GB97/032 | United Kingdom | ⤷ Start Trial | SPC/GB97/032: 20040802, EXPIRES: 20090801 |
| 0136011 | SPC/GB98/034 | United Kingdom | ⤷ Start Trial | SPC/GB98/034: 20040802, EXPIRES: 20090801 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch